Novartis Pruned Pipeline Producing Attractive Respiratory And Neurology Fruits, 2018 Report - ResearchAndMarkets.com

DUBLIN--()--The "Novartis Pruned Pipeline Producing Attractive Respiratory And Neurology Fruits" newsletter has been added to ResearchAndMarkets.com's offering.

During a London R&D meeting in November of 2018, Swiss giant Novartis AG announced it was paring back its pipeline from 430 products to 340.

Find out which areas are being phased out, and which are planned to become the company's main focus, including treatments for asthma and multiple sclerosis, and an immuno-oncology offering, as Scrip examines the short- and long-term pipeline for Novartis, under the direction of CEO Vas Narasimhan.

For more information about this newsletter visit https://www.researchandmarkets.com/r/awxt1u

Contacts

ResearchAndMarkets.com
Laura Wood, Senior Press Manager
press@researchandmarkets.com
For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
Related Topics: Respiratory Drugs, Central Nervous System Drugs

Contacts

ResearchAndMarkets.com
Laura Wood, Senior Press Manager
press@researchandmarkets.com
For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
Related Topics: Respiratory Drugs, Central Nervous System Drugs